Report
Matthieu DRIOL
EUR 108.16 For Business Accounts Only

Short term view - GENFIT : Rising consolidation.

The background trend is clearly bearish. The negative MACD confirms the trend. The rise is a consolidation that will soon bump against the level at €21.90.
The next target is at €17.80, then €16.50. Passing €28.28 would question the continuation of the fall.
Underlying
Genfit

Genfit is a biopharmaceutical company engaged in the discovery and development of drugs and biomarkers in therapeutic areas of high unmet need due to the lack of effective treatments or diagnostic tools and/or due to the increasing number of patients worldwide. Co. concentrates its research and development efforts to participate in the commercialization of treatment solutions and diagnostic tools to fight certain metabolic, inflammatory, autoimmune or fibrotic diseases affecting especially the liver (such as non-alcoholic steatohepatitis or "NASH").

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Matthieu DRIOL

Other Reports on these Companies
Other Reports from Day By Day
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch